A dangerous bird flu, in other words, was suddenly circulating in mammals—mammals with which people have ongoing, extensive ...
The H5N1 avian influenza virus is mutating to evade immune defenses in mammals following prior infection or vaccination.
Stock analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for Cocrystal Pharma in a research ...
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses ...
As scientists, we often think we understand a virus—its structure, its tricks, the way it moves through the body. But every ...
Viruses like SARS-CoV-2 use sugar molecules to hide from the immune system, but scientists at Scripps Research have designed ...
Equities research analysts at Zacks Small Cap issued their Q3 2025 earnings per share (EPS) estimates for Cocrystal Pharma in a research report issued to clients and investors on Tuesday, April 1st.
The current outbreak of the Asian Influenza virus in poultry may mutate to humans ... we add R9.5bn to the cost structure of the industry that's material, and that is then given through to the ...
Researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback